YD Bio (YDES) Assets Average (2025)
YD Bio (YDES) posted quarterly Assets Average of $9.8 million for Q4 2025, up 54.43% quarter-over-quarter from $6.4 million in Q2 2025.
YD Bio (YDES) Assets Average (2025) Analysis & Trends
YD Bio (YDES) has reported Assets Average for 1 consecutive years, with $9.8 million the latest figure, recorded in Q4 2025.
- In Q4 2025, Assets Average changed N/A year-over-year to $9.8 million; the TTM figure through Dec 2025 stood at $9.8 million (changed N/A YoY), while the FY2025 annual figure was $10.3 million, changed N/A from the prior year.
- Assets Average rose to $9.8 million in Q4 2025 per YDES's latest filing, from $6.4 million in the prior quarter.
- Across five years, Assets Average topped out at $9.8 million in Q4 2025 and bottomed at $6.4 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.57 Bn | 131.72 Bn | 2.84 Bn | 26.95 Bn |
| 2 | Regeneron Pharmaceuticals | 86.71 Bn | 78.72 Bn | 3.93 Bn | 41.30 Bn |
| 3 | Argenx Se | 65.44 Bn | 60.25 Bn | 1.37 Bn | - |
| 4 | Moderna | 60.06 Bn | 54.93 Bn | 52.00 Mn | 11.22 Bn |
| 5 | BeOne Medicines | 42.16 Bn | 37.06 Bn | 1.53 Bn | 8.86 Bn |
| 6 | Alnylam Pharmaceuticals | 31.89 Bn | 28.58 Bn | 992.69 Mn | 5.34 Bn |
| 7 | BioNTech SE | 28.11 Bn | 9.72 Bn | 668.28 Mn | 25.27 Bn |
| 8 | Insmed | 27.59 Bn | 26.43 Bn | 358.27 Mn | 2.09 Bn |
| 9 | Royalty Pharma | 27.33 Bn | 26.49 Bn | - | 19.82 Bn |
| 10 | YD Bio | 333.60 Mn | 327.59 Mn | - | 9.81 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 9.81 Mn |
| Jun 30, 2025 | 6.35 Mn |